The place of saxagliptin as a potential new treatment for patients with type 2 diabetes
Vienna, Austria, 29-Sep-09
Bailey, Prof. C., Birmingham, United Kingdom
The overall burden of type 2 diabetes
Holst, Prof. J. J., Copenhagen, Denmark
Scientific rationale for DPP-4 inhibition
Rosenstock, MD J., Dallas, United States
Clinical overview of saxagliptin
Barnett, Prof. A., Birmingham, United Kingdom
Achieving targets safely: role of DPP-4 inhibitors
Barnett, Prof. A., Birmingham, United Kingdom / Charbonnel, Prof. B., Nantes, France / Bornstein, Prof. S., Dresden, Germany / Bosi, Prof. E., Milan, Italy
The place of DPP-4 inhibitors in national guidelines – country-specific perspectives